Effect of Sodium Butyrate And Other Differentiation Inducers on Poorly Differentiated Human Ovarian Adenocarcinoma Cell Lines

Cancer Research

Volumn 48, Issue 21, 1988, Pages 6161-6165

  Langdon, Simon P ^a   Hawkes, Mary M ^a   Hay, Frances G ^a   Lawrie, Sandra S ^a   Schol, Dick J ^b   Hilgers, Jo ^b   Leonard, Robert C F ^a   Smyth, John F ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BUTYRIC ACID; CISPLATIN; DIMETHYL SULFOXIDE; DOXORUBICIN; FLUOROURACIL; HEXAMETHYLENEBISACETAMIDE; INTERFERON; N,N DIMETHYLFORMAMIDE; RETINOIC ACID; VINCRISTINE;

CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; FEMALE; HUMAN; HUMAN CELL; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

ADENOCARCINOMA; ALKALINE PHOSPHATASE; ANTIGENS, NEOPLASM; BUTYRATES; BUTYRIC ACID; BUTYRIC ACIDS; CELL DIFFERENTIATION; DIMETHYL SULFOXIDE; DNA, NEOPLASM; FATTY ACIDS; FEMALE; HUMAN; OVARIAN NEOPLASMS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0023700757     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Baak, J. P. A., Wisse-Brehelmans, E. C. M., Langley, F. A., Talerman, A., and Delemarre, J. F. M. Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours. J. Clin. Pathol., 39: 1340-1346, 1986.
2. Young, R. C., and DeVita, V. T., Jr. Ovarian carcinoma: Clinical trials, prognostic factors and criteria for response. In: M. J. Staquet (ed.), Prognostic Factors and Criteria of Response, pp. 319-335. New York: Raven Press, 1975.
3. Reiss, M., Gamba-Vitalo, C., and Sartorelli, A. C. Induction of tumor cell differentiation as a therapeutic approach: Preclinical models for hematopoietic and solid neoplasms. Cancer Treat. Rep., 70: 201-218, 1986.
4. Langdon, S. P., and Hickman, J. A. Alkylformamides as inducers of tumour cell differentiation-a mini-review. Toxicol., 43: 239-249, 1987.
5. Dexter, D. L., and Hager, J. C. Maturation-induction of tumor cells using a human colon carcinoma model. Cancer (Phila.), 45: 1178-1184, 1980.
6. Kim, Y. S., Tsao, D., Siddiqui, B., Whitehead, J. S., Arnstein, P., Bennet, J., and Hicks, J. Effects of sodium butyrate and dimethylsulfoxide on biochemical properties of human colon cancer cells. Cancer (Phila.), 45: 1185-1192, 1980.
7. Tsao, D., Morita, A., Bella, A., Jr., and Kim, Y. S. Differential effects of sodium butyrate. dimethylsulfoxide and retinoic acid on membrane associated antigen, enzymes and glycoproteins of human rectal adenocarcinoma cells. Cancer Res., 42: 1052-1058, 1982.
8. Higgins, P. J., Darzynkiewicz, Z., and Melamed, M. R. Secretion of albumin and α-foetoprotein by dimethylsulphoxide-stimulated hepatocellular carcinoma cells. Br. J. Cancer, 48: 485-493, 1983.
9. Dulbecco. R., Bologna, M., and Unger, M. Control of differentiation of a mammary cell line by lipids. Proc. Nati. Acad. Sci. USA, 77: 1551-1555, 1980.
10. Rudland. P. S., Davies, A. C. T., and Warburton. M. J. Prostaglandininduced differentiation or dimethylsulfoxide-induced differentiation: Reduction of the neoplastic potential of a rat mammary tumor stem cell line. J. Nati. Cancer Inst., 69: 1083-1093, 1982.
11. Joshi, S. J., Jackson. J. D., and Sharp, J. G. Differentiation inducing effects of butyrate and DMSO on human intestinal tumor cell lines in culture. Cancer Detect. Prevent., 8: 237-245, 1985.
12. Reese, D. H., Gratzner, H. G., Block, N. L., and Politano, V. A. Control of growth, morphology and alkaline phosphatase activity by butyrate and related short-chain fatty acids in the retinoid-responsive 9-1C rat prostatic adeno carcinoma cell. Cancer Res., 45: 2308-2313, 1985.
13. Chung, Y. S., Song. I. S., Erickson, R. H., Sleisenger, M. H., and Kim, Y. S. Effect of growth and sodium butyrate on brush border membrane-associated hydrolases in human colorectal cancer cell lines. Cancer Res., 45: 2976-2982, 1985.
14. Dexter, D. L., Lev, R., McKendall, G. R., Mitchell. P., and Calabresi. P. Sodium butyrate-induced alteration of growth properties and glycogen levels in cultured human colon carcinoma cells. Histochem. J., 16: 137-149, 1984.
15. Abe, M., and Kufe, D. W. Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells. Cancer Res., 44: 4574-4577, 1984.
16. Azuma. M., Hayashi, Y., Yoshida. H., Yanagawa, T., Yura. Y., Ueno, A., and Sato, M. Emergence of differentiated subclones from a human salivary adenocarcinoma cell clone in culture after treatment with sodium butyrate. Cancer Res., 46: 770-777, 1986.
17. Reese. D. H., Gordon, B., Gratzner, H. G., Claflin, A. J., Malinin, T. I., Block, N. L., and Politano, V. A. Effect of retinoic acid on the growth and morphology of a prostatic adenocarcinoma cell line cloned for the retinoid inducibility of alkaline phosphatase. Cancer Res., 43: 5443-5450, 1983.
18. Rudland, P. S., Paterson, F. C., Davies, A. C. T., and Warburton, M. J. Retinoid specific induction of differentiation and reduction of the DNA synthesis rate and tumor-forming ability of a stem cell line from a rat mammary tumor. J. Nati. Cancer Inst., 70: 949-958, 1983.
19. Collins, S. J., Ruscelli, F. W., Gallagher, R. E., and Gallo, R. C. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc. Nati. Acad. Sci. USA. 75: 2458-2462, 1978.
20. Breitman, T. R., Selonick, S. E., and Collins, S. J. Induction of differentiation of the human promyelocytic cell line (HL-60) by retinoic acid. Proc. Nati. Acad. Sci. USA, 77: 2936-2940, 1980.
21. Langdon, S. P., and Hickman, J. A. Correlation between the molecular weight and potency of polar compounds which induce the differentiation of HL-60 human promyelocytic leukemia cells. Cancer Res., 47: 140-144, 1987.
22. Cheson, B. D., Jasperse, D. M., Chun, H. G., and Friedman, M. A. Differentiating agents in the treatment of human malignancies. Cancer Treat. Rev., 13: 129-145, 1986.
23. Francis, G. E., and Pinsky, C. M. Clinical trials of differentiation therapy: Current trials and future prospects. In: S. Waxman, G. B. Rossi, and F. Takaku (eds.), The Status of Differentiation Therapy of Cancer, pp. 331-348. New York: Raven Press, 1988.
24. Novogrodsky, A., Dvir, A., Ravid, A., Shkolnik, T., Stenzel, K. H., Rubin, A. L., and Zaivov, R. Effect of polar organic compounds on leukemic cells: Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer (Phila.), 51: 9-14, 1983.
25. Miller, A. A., Kurschel, E., Schmidt, C. G., and Osieka, R. Clinical and pharmacological study of sodium butyrate in patients with acute leukemia. Proc. Am. Assoc. Cancer Res., 26: 1046, 1985.
26. Langdon, S. P., Lawrie, S. S., Hay, F. G., Hawkes, M. M., McDonald, A., Hayward, I. P., Schol, D., Hilgers, J., Leonard, R. C. F., and Smyth, J. F. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res., 48: 6166-6172, 1988.
27. Buick, R. N. Cell heterogeneity in human ovarian carcinoma. J. Cell. Physiol. SuppL. 3: 117-122, 1984.
28. Mackillop, W. J., and Buick, R. N. Cellular heterogeneity in human ovarian carcinoma studied by density gradient fractionation. Stem Cells, 1: 355-366, 1981.
29. Wolf,, C. R., Hayward, I. P., Lawrie, S. S., Buckton, K., McLntyre, M. A., Adams, D. J., Lewis, A. D., Scott, A. R. R., and Smyth, J. F. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int. J. Cancer, 39: 695-702, 1987.
30. Bancroft, J. D. Enzyme histochemistry. In: J. D. Bancroft and A. Stevens (eds.), Theory and Practice of Histological Techniques, pp. 287-304. Edinburgh, London and New York: Churchill Livingstone, 1977.
31. Lillie, R. D., and Ashburn, L. L. Supersaturated solutions of fat stains indilute isopropanol for demonstration of acute fatty degeneration not shown by Herxheimer's technic. Arch. Pathol., 36: 432-435, 1943.
32. Cook, H. C. Carbohydrates. In: J. D. Bancroft and A. Stevens (eds.), Theory and Practice of Histological Techniques, pp. 141-167. Edinburgh, London and New York: Churchill Livingstone, 1977.
33. Sternberger, L. A. The unlabelled antibody (PAP) method. J. Histochem. Cytochem., 27: 1657-1659, 1979.
34. Schol, D. J., Mooi, W. J., van der Gugten, A. A., and Hilgers, J. Monoclonal antibody 123C3, identifying small cell carcinoma phenotype in lung tumours, recognizes mainly, but not exclusively, endocrine and neuron-supporting normal tissues. Int. J. Cancer, 2: 34-40, 1988.
35. Mooi, W. J., Wagenaar, S. S., Schol, D. J., and Hilgers, J. Monoclonal antibody 123C3: Its value in lung tumour classification. Mol. Cell Probes, 2: 31-37, 1988.
36. Raemaker, F. C. S., Puts, J. J. G., Moesker, O., Kant, A., Huysmans, A., Haag, D., Jap, P. H. K., Herman, C. J., and Vooijs, G. P. Antibodies to intermediate filament proteins in the immunohistochemical identification of human tumours: An overview. Histochem. J., 15: 691-713. 1983.
37. Kabawat, S. E., Bast, R. C., Welch, W. R., Knapp, R. C., and Colvin, R. B. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors serous, endometrioid and clear cell types. Am. J. Clin. Pathol., 79: 98-104, 1983.
38. Makin, C. A., Bobrow, L. G., and Bodmer, W. F. Monoclonal antibodies to cytokeratin for use in routine histopathology. J. Clin. Pathol., 37: 975-983, 1984.
39. Burchell, J., Durbin, H., and Taylor-Papadimitriou, J. Complexity of expression of antigenic determinants recognised by monoclonal antibodies HMFG1 and HMFG2 in normal and malignant human mammary epithelial cells. J. Immunol., 131: 508-513, 1983.
40. Travers, P., and Bodmer, W. Preparation and characterization of monoclonal antibodies against placental alkaline phosphatase and other human tropho blast-associated determinants. Int. J. Cancer, 33: 633-641, 1984.
41. Courtenay, V. D., Selby, P. J., Smith, I. E., Mills, J., and Peckham, M. J. Growth of human tumour cell colonies from biopsies using two soft agar techniques. Br. J. Cancer, 38: 77-81, 1978.
42. Sartorelli, A. C. Malignant cell differentiation as a potential therapeutic approach. Br. J. Cancer, 52: 293-302, 1985.
43. Leder, A., and Leder, P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell. 5: 319-322, 1975.
44. Kruh, J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell. Biochem., 42: 65-82, 1982.
45. Candido, E. P. M., Reeves, R., and Davie, R. D. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 14: 105-113, 1978.
46. Sealy, L., and Chalkley, R. The effect of sodium butyrate on histone modification. Cell, 14: 115-121, 1978.
47. Cousens, L. S., Gallwitz, D., and Alberts, B. M. Different accessibilities in chromatin to histone acetylase. J. Biol. Chem., 254: 1716-1723, 1979.